Sonpiretigene Isteparvovec

Interim data from a GPCR-based optogenetic gene therapy add early human evidence to a mutation-agnostic approach for end-stage retinitis pigmentosa, a disease for which no broadly applicable approved treatment exists. Restore Vision Inc., a Tokyo-based clinical-stage biotechnology company, announced interim results from its Phase I/II trial of RV-001 optogenetic gene therapy, with data from six patients followed for up to 168 days. The open-label, dose-escalation study enrolled patients with no light perception across two cohorts of three patients each. All participants received a single intravitreal injection of RV-001, an adeno-associated virus vector encoding a chimeric rhodopsin designed to re-sensitize surviving inner retinal neurons to light. The primary endpoint is safety; exploratory assessments include visual acuity by logMAR chart, full-field stimulus testing, and functional vision tasks such as mobility and object recognition. No dose-limiting toxicities or drug-related serious adverse events were reported in either cohort. In the high-dose group, all three patients progressed from no light perception to light perception or better within one month, and one patient achieved chart-based visual acuity measurable by the Berkeley Rudimentary Vision Test. In the low-dose cohort, one of three patients reached light perception at approximately three months. The study remains ongoing, and the company said it plans to expand data collection across broader patient populations. Results were presented at Eyecelerator at ARVO 2026 and the Retinal Therapeutics Innovation Summit on May 1, 2026. Retinitis pigmentosa is caused by mutations in more than 70 genes, all converging on progressive rod and then cone photoreceptor degeneration. By the time patients reach the no-light-perception stage targeted in this trial, photoreceptors are largely absent, but downstream retinal interneurons — including bipolar and ganglion cells — often remain viable. That anatomical reality underpins the optogenetic approach: rather than replacing or correcting the causative mutation, the strategy is to render surviving inner retinal neurons light-sensitive by expressing an exogenous photosensitive protein. RV-001 delivers a chimeric rhodopsin that combines the cytoplasmic loops of vertebrate rhodopsin, which couple to native G-proteins and activate the endogenous phototransduction cascade, with the transmembrane scaffold of microbial rhodopsin, which confers self-regenerating chromophore properties independent of the retinal pigment epithelium visual cycle. The GPCR gene therapy design is intended to exploit signal amplification inherent to G-protein signaling, potentially enabling light detection under natural ambient conditions without external devices — a practical limitation of earlier channelrhodopsin-based approaches that required high-intensity light stimulation or goggles. The only approved gene therapy for any form of retinitis pigmentosa remains voretigene neparvovec (Luxturna, Spark Therapeutics), which targets biallelic RPE65 mutations — a subtype affecting roughly 1%–2% of RP patients. For the remaining patient population, no pharmacological or gene-based treatment has received regulatory approval. Supportive measures such as vitamin A supplementation and low-vision aids address neither disease progression nor restoration of function in advanced disease. The practical consequence is that patients with end-stage RP and no light perception — the population enrolled in this trial — currently have no therapeutic options. Mutation-specific gene replacement strategies are also largely inapplicable at this disease stage, as they depend on viable photoreceptors to rescue. This gap frames the clinical rationale for mutation-agnostic, restorative approaches such as optogenetic therapy for retinal disease. The field of optogenetic therapy for retinal disease has attracted multiple developers, with strategies diverging primarily on the choice of photosensitive protein and whether external devices are required. Nanoscope Therapeutics has advanced MCO-010, an AAV-delivered multi-characteristic opsin, into late-stage clinical development for RP, with randomized data reported. GenSight Biologics pursued GS030, a channelrhodopsin-based AAV therapy paired with light-stimulating goggles, in earlier human studies. Bionic Sight evaluated a channelrhodopsin program in advanced RP. All three rely on microbial ion channels rather than GPCR-mediated signaling, which the Restore Vision clinical trial results position as a mechanistic differentiator, at least theoretically. The interim Restore Vision clinical trial results are early-stage and drawn from a small, uncontrolled cohort. The convergence of signals across visual acuity, full-field stimulus testing, and functional vision tasks is notable given the severity of baseline impairment, but the data do not yet establish the durability, magnitude, or clinical meaningfulness of any functional gains. Expansion to broader patient populations, as the company has indicated, will be necessary to assess whether the GPCR gene therapy approach translates beyond this initial cohort. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Presentations will highlight the ongoing research behind potential bilateral and color vision benefits of Nanoscope's optogenetic therapy platform DALLAS , May 11, 2026 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced multiple presentations at the 29 th annual meeting of the American Society of Gene and Cell Therapy ( ASGCT 2026 ), to be held in Boston, May 11-15 th , 2026. Nanoscope's presentations will be centered around the company's MCO-010 optogenetic therapy for retinal degenerative diseases. MCO-010 is the most advanced program in the MCO (multi-characteristic opsin) platform and the first and only mutation-agnostic therapy shown to restore vision in patients with advanced retinitis pigmentosa (RP) via a one-time, standard intravitreal injection. "We are excited to present expanded clinical observations highlighting the potential patient benefit of MCO-treatment, along with key learnings from our AAV manufacturing efforts," said Dr. Samarendra Mohanty, co-founder and President of Nanoscope. "We look forward to sharing the important updates, including the positive therapeutic effects observed in RP and Stargardt disease patients, adding to our enthusiasm at Nanoscope as we near completion of the US BLA submission for MCO-010." Following are the details for the meeting presentations: Full Agenda Podium presentations: Bilateral functional improvement in patients following unilateral AAV-based retinal cell delivery of a bioengineered, synthetic protein with broad-spectrum light sensitivity Tuesday, May 12, 04:00 PM - 04:15 PM ET; MCEC Room 258ABC (Level 2) – Dr. Vinit Mahajan will present on bilateral observations following MCO-010 administration in nonclinical models and in clinical trials of patients with RP and Stargardt disease. Mechanism and clinical evidence of MCO-010 optogenetic therapy improving color discrimination in patients with outer retinal degeneration, Friday, May 15, 04:15 PM - 04:30 PM ET MCEC Room 210ABC (Level 2) – Dr. Samarendra Mohanty will present on color vision response in RP and Stargardt patients dosed with MCO-010, and the mechanism behind color sensitivity. Poster presentations: Orthogonal Quantitation of Replication-Competent AAV in AAV Manufacturing, Wednesday, May 13, 05:00 PM - 06:30 PM ET; Poster #2207 (MCEC Hall B2-C Exhibit Level) – Dr. Amir Singh presenting Chemistry, Manufacturing, and Controls (CMC) Challenges in Gene Therapy Regulatory Approvals: Insights from Approved Products and FDA Complete Response Letters, Wednesday, May 13, 05:00 PM - 06:30 PM ET; Poster #2235 (MCEC Hall B2-C Exhibit Level) – Dr. Ananta Ayyagari presenting Nanoscope team members will also be available for meetings during the ASGCT conference. About the MCO Platform MCO is a one-time, in-office, intravitreal disease-agnostic therapy platform designed to restore vision in patients with photoreceptor degeneration, including Retinitis Pigmentosa (RP), Stargardt disease (SD), and geographic atrophy (GA). By activating highly dense bipolar retinal cells to become light sensitive, MCO utilizes the remaining visual circuitry following photoreceptor death. MCO treatment does not require genetic testing, invasive surgery, or repeat dosing, enabling broad patient applicability within existing retina office workflows. About Nanoscope Therapeutics Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for retinitis pigmentosa (RP) ( NCT04945772 ), a rolling BLA submission to the FDA has been initiated. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) ( NCT05417126 ) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, as well as PMDA Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) and EMA, SFDA Orphan designations for IRDs. A Phase 2 program for MCO in geographic atrophy (GA) is expected to start in 2026. Other IND-ready programs include Leber congenital amaurosis (LCA). Contact: Nanoscope Therapeutics, Inc. +1 (817) 857-1186 PR@nanostherapeutics.com View original content to download multimedia: SOURCE Nanoscope Therapeutics